Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Usana Health Sciences (USNA) EBT (2016 - 2026)

Usana Health Sciences (USNA) has disclosed EBT for 17 consecutive years, with $4.2 million as the latest value for Q1 2026.

  • Quarterly EBT fell 59.95% to $4.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $41.5 million through Jan 2026, down 45.61% year-over-year, with the annual reading at $41.5 million for FY2026, 45.61% down from the prior year.
  • EBT for Q1 2026 was $4.2 million at Usana Health Sciences, up from $1.8 million in the prior quarter.
  • The five-year high for EBT was $47.2 million in Q1 2022, with the low at $1.8 million in Q3 2025.
  • Average EBT over 5 years is $22.1 million, with a median of $22.8 million recorded in 2022.
  • The sharpest move saw EBT grew 16.7% in 2023, then crashed 90.36% in 2025.
  • Over 5 years, EBT stood at $22.8 million in 2022, then rose by 16.7% to $26.6 million in 2023, then tumbled by 60.81% to $10.4 million in 2024, then tumbled by 82.8% to $1.8 million in 2025, then skyrocketed by 132.83% to $4.2 million in 2026.
  • According to Business Quant data, EBT over the past three periods came in at $4.2 million, $1.8 million, and $18.8 million for Q1 2026, Q3 2025, and Q2 2025 respectively.